American Society of Hirudotherapy

Efficacy and safety of Xa inhibitors for the treatment of cancer-associated venous thromboembolism

Narrative review published in Expert opinion on drug safety (2019)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Narrative reviewDrug DevelopmentKimpton et al. · Expert opinion on drug safety, 2019

Abstract

INTRODUCTION: Cancer patients with cancer-associated thrombosis (CAT) are at an elevated risk of recurrent venous thromboembolism (VTE) and of major bleeding while receiving treatment with anticoagulation. Recently, Xa inhibitors have been assessed in cancer patients for the treatment of CAT, providing clinicians and patients with more treatment options. AREAS COVERED: In this narrative review, the authors evaluate the evidence regarding the efficacy and safety of edoxaban, rivaroxaban, and apixaban in the treatment of CAT. EXPERT OPINION: Xa inhibitors are an effective, safe, and convenient option for the treatment of CAT. Overall, they may be associated with a lower risk of recurrent VTE in cancer patients. Certain subgroups of cancer patients may be at increased risk of major bleeding while on treatment with Xa inhibitors, when compared to low-molecular-weight-heparin (LMWH). The current published data suggests an increase in gastrointestinal (GI) major bleeding in patients with GI malignancies. Other patient, treatment, and cancer characteristics may also be associated with a higher risk of major bleeding. Therefore, when assessing the appropriateness of Xa inhibitors for the treatment of CAT, the clinician must take into consideration the known interactions of these drugs, the individualized bleeding risk, and the patient's preferences, in order to make the best possible anticoagulation therapy recommendation.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsFactor Xa InhibitorsHemorrhageHumansNeoplasmsPyrazolesPyridinesPyridonesRivaroxabanThiazolesVenous Thromboembolism

Summary

This narrative review assesses edoxaban, rivaroxaban, and apixaban for cancer-associated thrombosis, concluding these factor Xa inhibitors are effective and convenient, possibly lowering recurrent VTE risk, though gastrointestinal malignancies carry heightened major bleeding risk.

Context

This narrative review evaluates the published evidence on factor Xa inhibitors (edoxaban, rivaroxaban, apixaban) for treating cancer-associated venous thromboembolism, concluding they are effective, safe, and convenient and may lower recurrent VTE risk versus low-molecular-weight heparin, while flagging higher major-bleeding risk in certain subgroups, notably gastrointestinal major bleeding in patients with GI malignancies. It serves as background on how the anticoagulation field has evolved, the same therapeutic problem that the leech's salivary anticoagulants historically illuminated and that frames the leech-secretome drug-discovery narrative. As a narrative review it summarizes and interprets others' studies rather than generating new data, its expert-opinion conclusions are not a substitute for the primary trials, and it addresses pharmacologic anticoagulants only, with no medicinal-leech or hirudin content.

Citation

Reference (Vancouver style)

Kimpton M, Carrier M. Efficacy and safety of Xa inhibitors for the treatment of cancer-associated venous thromboembolism. Expert Opin Drug Saf. 2019;18(4):313-320. doi:10.1080/14740338.2019.1601699. PMID: 30925842

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 29, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.